Please assess the completion status of the following clinical trial:

Trial Title: Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed melanoma, either unresectable stage IIIc or stage IV metastatic melanoma, as defined by AJCC 7th edition.~* Patients must be naïve to treatment for locally advanced unresectable or metastatic disease. Prior immunotherapy (including ipilimumab) is allowed.~* Documentation of BRAFV600E or BRAFV600K mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples).~* Measurable disease per RECIST v1.1, which are accessible to biopsies.~* Biopsy lesion is within scan reach of diagnostic CT and PET-CT (thorax- abdomen-pelvis)~* ECOG performance status of 0 or 1.~* Male or female patient aged ≥ 18 years.~* Life expectancy ≥ 12 weeks.~* Adequate hematologic and end organ function within 14 days prior to first dose of study drug treatment.~Exclusion Criteria:~* History of prior RAF or MEK pathway inhibitor treatment.~* Palliative radiotherapy, major surgery or traumatic injury within 14 days prior to the first dose of study treatment.~* Active malignancy within the past 3 years other than melanoma that could potentially interfere with the interpretation of efficacy measures, except for patients with resected BCC or SCC of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast.~* History of or evidence of retinal pathology, clinically significant cardiac dysfunction, patients with active CNS lesions, renal or liver dysfunction as described in main protocol (REPOSIT NL48639.031.14).~* Pregnant, lactating, or breast-feeding.~* Unwillingness or inability to comply with study and follow-up procedures (i.e. severe anxiety disorder preventing PET/CT imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with BRAF/MEK inhibitor (Type: EXPERIMENTAL): Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).